JAMA ATTAIN-OSA: Oral Orforglipron Cut Apnea-Hypopnea Index by an Extra 12 to 13 Events an Hour in 712 Adults Over 52 Weeks

Two phase 3 randomized trials in the ATTAIN-OSA program, published online in JAMA on November 9, 2026, and presented at the American Heart Association Scientific Sessions, found that once-daily oral orforglipron significantly reduced the apnea-hypopnea index (AHI) over 52 weeks in adults with moderate to severe obstructive sleep apnea (OSA) and obesity or overweight. Orforglipron, developed by Eli Lilly and Company, is approved for weight management; it is not approved for sleep apnea, and Lilly plans to submit it to the U.S. Food and Drug Administration for that use by the end of 2026.
The two multicenter, double-blind, placebo-controlled trials randomized 712 patients in total: 363 in trial 1, who were not receiving positive airway pressure (PAP) therapy, and 349 in trial 2, who had been receiving PAP for at least 3 months. Participants had moderate to severe OSA and a body mass index of at least 27, without type 1 or type 2 diabetes. The trials ran at 66 sites in nine countries, with outcomes assessed from baseline to week 52.
At week 52, AHI fell by 17.8 events an hour with orforglipron versus 4.5 with placebo in trial 1, a difference of minus 13.2 events an hour; in trial 2 the falls were 17.3 versus 5.3 events an hour, a difference of minus 12.0. Six of seven key secondary endpoints significantly favored orforglipron. Gastrointestinal events were most common: in trial 1, 123 of 181 patients (68.0%) on orforglipron versus 68 of 182 (37.4%) on placebo; in trial 2, 125 of 177 (70.6%) versus 63 of 172 (36.6%).
JAMA's summary notes the trials lasted only 52 weeks, most participants had severe OSA, racial and ethnic diversity was low, and patients with diabetes, a body mass index below 27, or mild OSA were excluded, so longer-term studies in broader populations are needed. This report presents trial facts and regulatory status only and makes no individual treatment recommendation.
Source: JAMA
Published by GSM · USA (original Chinese edition)
Photo: 图中是一台持续正压通气(CPAP)呼吸机及面罩。图源:Wikimedia Commons(File:CPAP machine.jpg),作者 Mnalis,授权 CC0 1.0。

